Biography:Frédéric Y. Bois

From HandWiki
Frederic Y. Bois
Frederic Y Bois 2008.png
Born1958 (age 65–66)
NationalityFrench
Alma materPaul Verlaine University – Metz, France
Known for
  • Pharmacokinetics
  • Bayesian Statistics
Awards
  • American Statistical Association "Outstanding Statistical Application Award"
  • French Epidaure Prize for Environmental Health Research
  • National Order of Merit (France)
  • Ordre des Palmes Académiques
Scientific career
FieldsSystems Toxicology
InstitutionsCERTARA, Simcyp division

Frédéric Yves Bois, Pharm.D.Ph.D. (born 1958) is a French biological scientist working in toxicology and bioinformatics.[1][2] He is currently Research Director at the French Institut National de l'Environnement et des Risques (INERIS).

Biography

Frédéric Bois was born in Limoges, France, in 1958. He obtained his Pharm.D. from the Université de Nancy (1981) and his Ph.D. from the University of Metz (1988). Most of his Ph.D. thesis, on the use of physiologically based pharmacokinetic models and stochastic carcinogenesis models for risk assessment, was developed at the Harvard University Energy and Environmental Policy Center (in Richard Wilson's group at the Jefferson Physical Laboratory). His post-doctoral research was performed at UCSF and UC Berkeley School of Public Health. He then held joint appointments at the California Environmental Protection Agency (under the direction of Dr. Lauren Zeise) and the Lawrence Berkeley National Laboratory (in the group of Dr. Joan Daisey). Upon his return to France he worked at INSERM (in the group of Pr. A.-J. Valleron) until 1998. He was Research Director at the INERIS research lab from 1999 to 2019. From 2009 to 2015 he was also incumbent of Chair of Mathematical Modelling for Systems Toxicology of the Université de Technologie de Compiègne. He is now Senior Scientific Advisor in the Simcyp division of the Certara Company [3]. He is married to Nicole Cancré and they have four children: Pauline, Jules, Eugène and Camille.

He is member of the French :fr:Comité de la prévention et de la précaution,[1] scientific editor for "In Silico Pharmacology"[4] and "Environnement, Risque et Santé"[5]

Work

Frédéric Y. Bois has worked at the Energy and Environmental Policy Center at Harvard University (1985-1987), in the research group of Pr. Richard Wilson (Jefferson Laboratory) during his PhD thesis. His work focused on physiologically based pharmacokinetic (PBPK) modeling and stochastic cancer models, applied to vinyl chloride. He then worked as a post-doctoral scientist at the University of California, San Francisco School of Pharmacy with Pr. Thomas Tozer (1988) and at the University of California, Berkeley School of Public Health (1989), focusing on Monte-Carlo based uncertainty analysis of PBPK models. During a joint appointment at the California Environmental Protection Agency and at the Lawrence Berkeley National Laboratory he developed, in collaboration with Andrew Gelman, the application of Bayesian numerical approaches to multilevel PBPK models. He directed several research projects for the US Food and Drug Administration, the National Institute of Health, the Environmental Protection Agency, and the Occupational Safety and Health Administration. He contributed mostly to the fields of bioequivalence testing, health risk assessment,[6] population pharmacokinetics and Bayesian statistics. He is the developer, together with D. Mazsle, of the GNU MCSim software.

He is currently Research Director at the Institut national de l'environnement industriel et des risques (INERIS) where he coordinated to the European integrated project 2FUN (https://web.archive.org/web/20131028035939/http://www.2-fun.org/), and participated to several others (ACUTEX, NANOSAFE 2, PREDICT-IV, StemBANCC). His recent work is on Physiologically based pharmacokinetic modelling, bioinformatics and systems biology.

He is member or past member of US National Research Council Standing Committee on Risk Analysis Issues and Reviews,[7] the American Association for the Advancement of Science, the Society for Mathematical Biology, the European Science Foundation-EERO Association, the French Statistical Society, the French National Association for Technological Research. He is a recipient of the American Statistical Association "Outstanding Statistical Application Award"[8] and of the French Epidaure Prize for Environmental Health Research.

Positions and awards

  • 1984 Fall: Visiting Scientist, Division of Environmental Carcinogenesis, International Agency for Research on Cancer, Lyon, France.
  • 1986-87: Research Associate, Energy and Environmental Policy Center, Harvard University, Cambridge, USA.
  • 1987-88: Post-Doctoral Research Biologist, University of California Medical Center, San Francisco, USA.
  • 1988-90: Post-Graduate Researcher VII, School of Public Health, University of California, Berkeley, USA.
  • 1991-96: Staff Toxicologist (Specialist), Reproductive and Cancer Hazard Assessment Section, California Environmental Protection Agency, Berkeley, USA.
  • 1991-99: Staff Scientist, Lawrence Berkeley Laboratory, Berkeley, USA.
  • 1992-93: Maître de Conférence Associé, Faculté des Sciences Pharmaceutiques et Biologiques, Université de Nancy, France.
  • 1996: October–December: Visiting Professor, School of Public Health, University of California, Berkeley, USA.
  • 1995-99: Visiting Scientist, Unité INSERM 444 (Biomathématiques, Biostatistiques et Epidémiologie), Paris.
  • 1999: Visiting Scientist, Lawrence Berkeley Laboratory, Berkeley, USA.
  • 1999-2000: Research Scientist, INERIS, Verneuil en Hallate, France.
  • 2000-04: Head of the Experimental Toxicology Laboratory, INERIS, Verneuil en Hallate, France.
  • 2002: Knight, National Order of Merit (France)
  • 2009-2015: Professor, Chair of Mathematical Modelling for Systems Toxicology, UTC, Compiègne, France.
  • 2004-: Scientific Officer, Division of Chronic Risks, INERIS, Verneuil en Hallate, France.
  • 2017: Knight, Ordre des Palmes Académiques (France)

Publications

  • Bois F., Golbamaki-Bakhtyari N., Kovarich S., Tebby C., Gabb H.A., Lemazurier E., 2017, A high-throughput analysis of ovarian cycle disruption by mixtures of aromatase inhibitors, Environmental Health Perspectives, 077012-1, doi:10.1289/EHP742.
  • Datta, S., Gayraud, G., Leclerc, E., Bois, F., 2017, Graph_sampler: a simple tool for fully Bayesian analyses of DAG-models, Computational Statistics, 32:691-716. doi: 10.1007/s00180-017-0719-1.
  • Raja P.M.V., Lacroix G., Sergent J.-A., Bois F., Barron A.R., Monbelli E., Elgrabli D., 2017, Nanotoxicology: role of physical and chemical characterization and related in vitro, in vivo, and in silico methods, in Metrology and Standardization for Nanotechnology: Protocols and Industrial Innovations, first edition, Mansfield E., Kaiser D.L., Fujita D., Van de Voorde M. Eds, Wiley-VCH Verlag, p. 363-379.
  • Grech A., Brochot C., Dorne J.-L., Quignot N., Bois F., Beaudouin R., 2017, Toxicokinetic models and related tools in environmental risk assessment of chemicals, Science of the Total Environment, 578: 1-15, doi: 10.1016/j.scitotenv.2016.10.146.
  • Zgheib E., Bechaux C., Crepet A., Mombelli E., Bois F., 2017, High-throughput methods for toxicology and health risk assessment, Environnement, Risques et Santé, 16:44-58.
  • Cote I., Andersen M., Ankley G.T., Barone S., Birnbaum L.S., Boekelheide K. Bois F. et al., 2016, The Next Generation of Risk Assessment Multi-Year Study - Highlights of findings, applications to risk assessment, and future directions, Environmental Health Perspectives, 124:1671-1682, doi: 10.1289/EHP233.
  • Nicoulaud-Gouin V., Giacalone M., Attard J.-C., Martin-Garin A., Garcia-Sanchez L., Bois F., 2016, Parameter identification and comparison of radionuclides transfer models using a Bayesian approach, Journal of Environmental Radioactivity, 162-163: 328-339, doi: 10.1016/j.jenvrad.2016.06.008.
  • Bois F., Brochot C., 2016, Modeling pharmacokinetics, in In Silico Methods for Predicting Drug Toxicity, Benfenati E. Ed., Methods in Molecular Biology Series, 1425:37-62, Humana Press, New-York, doi: 10.1007/978-1-4939-3609-0_3.
  • Leclerc E., Hamon J. Bois F., 2016, Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models, Journal of Applied Toxicology, 36:330-339.
  • Péré H., Rascanu A., LeGoff J., Matta M., Bois F., Lortholary O., Leroy V.,Launay O., Bélec L. and the ANRS EP24 study group, 2015, Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1- co-infected women receiving effective combined antiretroviral therapy, International Journal of STD & AIDS, 27:178-185, doi:10.1177/0956462415577727.
  • Hamon J., Renner M., Jamei M., Lukas A., Kopp-Schneider A., Bois F, 2015, Quantitative in vitro to in vivo extrapolation of tissues toxicity, Toxicology in Vitro, 30:203-216.
  • Mueller S., Dekant W., Jennings P., Testai E., Bois F., 2015, Predict-IV: a systems toxicology approach to improve pharmaceutical drug safety testing. Toxicology in Vitro, 30: 4-6.
  • Crean D., BellwonfP., Aschauer L., Limonciel A., Moenks K., Hewitt P., Schmidt T., Herrgen K., Dekant W., Lukas A., Bois F., Wilmes A., Jennings P., Leonard M.O., 2015, Adefovir accumulates and its toxicity enhanced in renal epithelial cells exposed to hypoxic stress, Toxicology in Vitro, 30:128-137.
  • Pomponio G., Savary C., Parmentier C., Bois F., Guillouzo A., Romanelli L., Richert L., Di Consiglio E., Testai E., 2015, In vitro kinetics of amiodarone and its major metabolite in two human-derived cell models after acute and repeated exposure, Toxicology in Vitro, 30:36-51.
  • Bellwon P., Truisi G.L., Bois F., Wilmes A., Schmidt T., Savary C.C., Parmentier C., Hewitt P., Schmal O., Josse R., Richert L., Mueller S.O., Jennings P., Testai E., Dekant W.,2015, Kinetics and dynamics of cyclosporine A in three hepatic cell culture systems, Toxicology in Vitro, 30:62-78.
  • Wilmes A., Bielow C., Ranninger C., Bellwon P., Aschauer L., Limonciel A., Chassaigne H., Kristl T., Aiche S., Huber C.G., Guillou C., Hewitt P., O Leonard M.O., Dekant W., Bois F., Jennings P., 2015, Mechanism of cisplatin proximal tubule toxicity revealed by integrating, transcriptomics, proteomics, metabolomics and biokinetics, Toxicology in Vitro, 30:117-127. doi: 10.1016/j.tiv.2014.10.006.
  • Gould A.L., Boye M.E., Crowther M.J., Ibrahim J.G., Quartey G., Micallef S., Bois F., 2015, Joint Modeling of Survival and Longitudinal Non-Survival Data: Current Methods and Issues. Report of the DIA Bayesian Joint Modeling Working Group [with discussion]. Statistics in Medicine, 34:2181-2203, doi:10.1002/sim.6141.
  • Rovida C., Alépée N., Api A.M., Basketter D.A., Bois F., Caloni F, et al., 2015, Integrated Testing Strategies (ITS) for safety assessment. ALTEX, 32:25–40.
  • Truisi G., Di Consiglio E., Parmentier C., Savary C., Pomponio G., Bois F., Lauer B., Josse R., Hewitt P., Mueller S., Richert L., Guillouzo A., Testai E., 2015, Understanding the biokinetics of ibuprofen after single and repeated treatments in rat and human in vitro liver cell systems, Toxicology Letters, 233:172-186, doi: 10.1016/j.toxlet.2015.01.006.
  • Bricks T., Hamon J., Fleury M.J., Jellali R., Merlier F., Herpe Y.E., Seyer A., Regimbeau J-M., Bois F., Leclerc E., 2015, investigation of omeprazole and phenacetin first-pass metabolism in humans using a microscale bioreactor and pharmacokinetic models, Biopharmaceutics and Drug Disposition, 36:275-293, doi:10.1002/bdd.1940.
  • Leclerc E., Hamon J., Claude I., Jellali R., Naudot M., Bois F., 2015, Investigation of acetaminophen toxicity in HepG2/C3a microscale cultures using a system biology model of glutathione depletion, Cell Biology and Toxicology, 31:173-185, doi:10.1007/s10565-015-9302-0.
  • Bois F., Gayraud G., 2015, Probabilistic generation of random networks taking into account information on motifs occurrence, Journal of Computational Biology, 22:25-36, doi:10.1089/cmb.2014.0175.
  • Prot J.M., Maciel L., Bricks T., Merlier F., Cotton J., Paullier P., Bois F., Leclerc E., 2014, First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans, Biotechnology and Bioengineering, 111:2027-2040.
  • Hamon J., Jennings P., Bois F., 2014, Systems biology modeling of omics data: effect of cyclosporine a on the Nrf2 pathway in human renal cells. BMC Systems Biology 8:76, doi: 10.1186/1752-0509-8-76.
  • Leclerc E., Hamon J., Legendre A., Bois F., 2014, Integration of pharmacokinetic and NRF2 system biology models to describe reactive oxygen species production and subsequent glutathione depletion in liver microfluidic biochips after flutamide exposure, Toxicology in Vitro, 28:1230–1241.
  • Quignot N., Hamon J., Bois F., 2014, Extrapolating in vitro results to predict human toxicity, in In Vitro Toxicology Systems, Bal-Price A., Jennings P., Eds, Methods in Pharmacology and Toxicology series, Springer Science, New York, USA, p. 531-550.
  • Baudoin R., Legendre A., Jacques S., Cotton J., Bois F., Leclerc E., 2014, Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats, Journal of Pharmaceutical Sciences 103:706-718.
  • Bessems J., Loizou G., Krishnan K., Clewell H.J., Bernasconi C., Bois F., et al., 2014, PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment. Recommendations from a joint EURL ECVAM - EPAA workshop, Regulatory Toxicology and Pharmacology 68:119-139.
  • Rappaport S., Johnson B., Bois F., Kupper L., Kim S., Thomas R., 2013, Ignoring and adding errors do not improve the science, Carcinogenesis 34:1689-1691, doi: 10.1093/carcin/bgt100.
  • Geenen S., Yates J., Kenna J.G., Bois F., Wilson I.D., Westerhoff H.V., 2013, Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and glutathione-depleting biomarkers ophthalmic acid and 5- oxoproline in humans and rats, Integrative Biology. 5:877-888.
  • Ramirez T., Daneshian M., Kamp H., Bois F., et al., 2013, Metabolomics in Toxicology and Preclinical Research, ALTEX - Alternatives to Animal Experimentations, 30:209-225.
  • Bois F., Gayraud G., 2013, Probabilistic generation of random networks taking into account information on motifs occurrence, arXiv:1311.6443 [q-bio.QM].
  • Bois F., 2013, Computational pharmacokinetics at a crossroads, In Silico Pharmacology, 1:5.
  • Wilmes A., Limonciel A., Aschauer L., Moenks K., Bielow C., Leonard M.O., Hamon J., Carpi D., Ruzek S., Handler A., Schmal O., Herrgen K., Bellwon P., Burek C., Truisi G.L., Hewitt P., Di Consiglio E., Testai E., Blaauboer B.J., Guillou C., Huber C.G., Lukas A., Pfaller W., Mueller S.O., Bois F., Dekant W., Jennings P., 2013, Integrated omic profiling reveals novel insights of cyclosporine A induced cellular stress, Journal of Proteomics, 79:180-194, doi: 10.1016/j.jprot.2012.11.022.
  • Quignot N., Bois F., 2013, A computational model to predict rat ovarian steroid secretion from in vitro experiments with endocrine disruptors, PLoS ONE, 8(1): e53891, doi:10.1371/journal.pone.0053891.
  • Rappaport S., Kim S., Thomas R., Johnson B., Bois F., Kupper, L., 2013, Low-dose metabolism of benzene in humans: science and obfuscation, Carcinogenesis, 34:2-9, doi: 10.1093/carcin/bgs382.
  • Zeise L., Bois F., Chiu W.A., Hattis D.B., Rusyn I., Guyton K.Z., 2013, Addressing human variability in next generation health assessments of environmental chemicals, Environmental Health Perspectives, 121:23-31, doi: 10.1289/ehp.1205687.
  • Coecke S., Pelkonen O., Batista Leite S., Bernauer U., Bessems J., Bois F., Gundert-Remy U., Loizou G., Testai E., Zaldívar J.M., 2013, Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches, Toxicology in Vitro, 27:1570-1577, doi: 10.1016/j.tiv.2012.06.012.
  • Bois F., 2012, Bayesian inference, in Computational Toxicology vol. II, Reisfeld B., Mayeno A.N. Eds., Methods in Molecular Biology Series, 930:597-636, Humana Press, New-York, doi: 10.1007/978-1-62703-059-5_25.
  • Dorne J.L., Amzal P., Bois F., Crepet A., Tressou J., Verger P., 2012, Population effects and variability, in Computational Toxicology vol. I, Reisfeld B., Mayeno A.N. Eds., Methods in Molecular Biology Series, 929:521-581, Humana Press, New-York, doi: 10.1007/978-1-62703-050-2_20.
  • Bois F., Jamei M., 2012, Population-based pharmacokinetic modeling and simulation, in Encyclopedia of Drug Metabolism and Interactions, Lyubimov A.V., Ed., John Wiley & sons, Hoboken, vol. XI, p. 1-27, doi: 10.1002/9780470921920.edm135.
  • Prot J.M., Bunescu A., Elena-Hermann B., Aninat C., Snouber L., Griscom L., Razan F., Bois F., et al., 2012, Predictive toxicology using systemic biology and liver microfluidic approaches¬†: application to acetaminophen injury, Toxicology and Applied Pharmacology, 259:270-280.
  • Coecke S., Pelkonen O., Batista Leite S., Bernauer U., Bessems J., Bois F., Gundert-Remy U., Loizou G., Testai E., Zaldivar J.M., 2012, Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches, Toxicology in Vitro, doi: 10.1016/j.tiv.2012.06.012.
  • Cheng S., Prot J.-M., Leclerc E., Bois F., 2012, Zonation-related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions, BMC Genomics, 19:54.
  • Cheng S., Bois F., 2011, A mechanistic modeling framework for predicting metabolic interactions in complex mixtures, Environmental Health Perspectives, 119:1712-1718.
  • Ngo L., Ryan L.M., Mezzetti M., Bois F., Smith T.J., 2011, Estimating metabolic rate for butadiene at steady state using a Bayesian physiologically-based pharmacokinetic model, Journal of Environmental and Ecological Statistics, 18:131-146, doi: 10.1007/s10651-009-0124-1.
  • Adler S., Basketter D., Creton S., Pelkonen O., van Benthem J., Zuang V., Ejner Andersen K., Angers-Loustau A., Aptula A., Bal-Price A., Benfenati E., Bernauer U., Bessems J., Bois F., et al., 2011, Alternative (non-animal) methods for cosmetics testing: current status and future prospect - 2010, Archives of Toxicology, 85:367-485.
  • Baeza-Squiban A., Lacroix G., Bois F., 2011, Experimental Models in Nanotoxicology, in Nanoethics and Nanotoxicology, Lahmani M., Marano F., Eds. Springer Verlag, Berlin Heidelberg, p. 63-86.
  • Bois F., Jamei M., Clewell H.J., 2010, PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals, Toxicology, 278:256-267.
  • Bois F., 2010, Physiologically-based modelling and prediction of drug interactions, Basic and Clinical Pharmacology and Toxicology, 106¬†:154-161, doi: 10.1111/j.1742-7843.2009.00488.x.
  • Bois F., Habka D., Brochot C., 2010, An integrated modelling approach for in vitro to in vivo extrapolations, ALTEX - Alternatives to Animal Experimentations, 27:103-108.
  • Martin A., Bois F., Pierre F., Wild P., 2010, Occupational exposure to cobalt : a population toxicokinetic modelling approach validated by field results challenges the Biological Exposure Index for urinary cobalt, Journal of Occupational and Environmental Hygiene, 7:54-62.
  • Bois F., 2009, [Physiological modeling of metabolic interactions], Environnement, Risque et Sante, 8:413-424.
  • Bois F., 2009, GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models, Bioinformatics, 25:1453-1454, doi: 10.1093/bioinformatics/btp162.
  • Pery A., Bois F., 2009, Adaptation of PBPK model equations to study compound concentration stochasticity in cells and cancer risk assessment, Risk Analysis, 29:1182-1191, doi: 10.1111/j.1539-6924.2009.01242.x.
  • Pery A., Brochot C., Hoet P., Nemmar A., Bois F., 2009, Development of a physiologically-based kinetic model for 99m-Technetium labelled carbon nanoparticles inhaled by humans, Inhalation Toxicology, 21:1099-1107, doi: 10.3109/08958370902748542.
  • Baeza-Squiban A., Lacroix G., Bois F., 2009, [Experimental Models in Nanotoxicology], in [Nanosciences: Nanotoxicology, Nanoethics], Houdy P., Lahmani M., Marano F., Eds., Belin, Paris.
  • Woodruff T.J., Zeise L., Axelrad D.A., Guyton K.Z., Janssen S., Miller M., Miller G.G., Schwartz J.M., Alexeeff G., Anderson H., Birnbaum L., Bois F., Cogliano V.J., Crofton K., Euling S.Y., Foster P.M.D., Germolec D.R., Gray E., Hattis D.B., Kyle A.D., Luebke R.W., Luster M.I., Portier C., Rice D.C., Solomon G., Vandenberg J., Zoeller R.T., 2008, Moving upstream: Evaluating adverse upstream endpoints for improved risk assessment and decision-making, Environmental Health Perspectives, 116:1568-1575.
  • Verger P., Bard D., Noiville C., Lahidji R., The French Committee for Prevention and Precaution, 2008, Environmental disasters: preparing for impact assessments and operational feedback, American Journal of Disaster Medicine, 3:358-368.
  • Smith T., Bois F., Lin Y.-S., Brochot C., Micallef S., Kim D., Kelsey K.T., 2008, Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures, Journal of Breath Research, 2:037018 (10 p.)
  • Loizou G., Spendiff M., Barton H.A., Bessems J., Bois F., Bouvier d'Yvoire M., Buist H., Clewell H.J.III, Meek B., Gundert-Remy U., Goerlitz G., Schmitt W., 2008, Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps, Regulatory Toxicology and Pharmacology, 50:400-411.
  • Bouvier d'Yvoire M., Prieto P., Blaauboer B.J., Bois F., et al., 2007, Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda - The report and recommendations of ECVAM Workshop 63a, Alternatives to Laboratory Animals, 35:661-671.
  • Barton H.A., Chiu W.A., Setzer W., Andersen M.E., Bailer A.J., Bois F., DeWoskin R.S., Hays S., Johanson G., Jones N., Loizou G., MacPhail R.C., Portier C.J., Spendiff M., Tan Y.-M., 2007, Characterizing uncertainty and variability in physiologically-based pharmacokinetic (pbpk) models: state of the science and needs for research and implementation, Toxicological Sciences, 99: 395-402.
  • Chiu W.A., Bois F., 2007, An approximate method for population toxicokinetic analysis with aggregated data, Journal of Agricultural, Biological, and Environmental Statistics, 12:346-363.
  • Baulig A., Penelon T., Pichard A., Bois F., 2007, [Uncertainties and acute toxicity thresholds in accident situations], Environnement, Risque et Sant√©, 6:119-126.
  • Brochot C., Smith T.J., Bois F., 2007, Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues, Chemico-Biological Interactions, 167:168-183.
  • Micallef S., Amzal B., Bach V., Chardon K., Tourneux P., Bois F., 2007, Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates, Clinical Pharmacokinetics, 46:59-74.
  • Chiu W.A., Micallef S., Monster A.C., Bois F., 2007, Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: Empirical results and comparisons with previous studies, Toxicological Sciences, 95:23-36.
  • Jonsson F, Jonsson E.N., Bois F., Marshall S., 2007, The application of a Bayesian approach to the analysis of a complex, mechanistically based model, Journal of Biopharmaceutical Statistics, 17:65-92.
  • Brochot C., Bessoud B., Balvay D., Cuenod C.-A., Siauve N., Bois F., 2006, Evaluation of antiangiogenic treatment effects on tumors microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging, Magnetic Resonance Imaging, 24:1059-1067.
  • Amzal B., Bois F., Parent E., Robert C.P., 2006, Bayesian optimal design via interacting MCMC, Journal of the American Statistical Association, 101:773-785.
  • Noiville C., Bois F., Hubert P., Lahidji R., Grimfeld A., 2006, Opinion of the Committee for Prevention and Precaution about the precautionary principle, Journal of Risk Research, 9:247-296.
  • Chiu W.A., Bois F., 2006, Revisiting the population toxicokinetics of tetrachloroethylene, Archives of Toxicology, 80:386-.
  • Bois F., Boudet C., 2006, Integrating environmental monitoring and human biomarker data in risk assessment: The role of modeling. Epidemiology 17(6):S75-S75 Suppl. S. (non refereed)
  • Brulez C., Jacobs S., Jones M., Simpson E., Lecomte A., Robidel F., Bois, F., Lemazurier, E., 2006, A new in vivo model to screen both estrogenic and anti-/androgenic compounds, Epidemiology 17(6):S332-S333 Suppl. S. (non refereed)
  • Desmots S., Lecomte A., Robidel F., Dupont O., Bois F., Lemazurier E., 2006, Expression of both mrp1 and mdr1 genes, two members of the ABC transporter family, is modulated by the estrogenic environmental pesticide methoxychlor, Epidemiology 17(6):S334-S334 Suppl. S. (non refereed)
  • Bois F., 2006, [Epidemiological Modeling], in [Human Epidemiology - Conditions for its Development in France and the Role of Mathematics], Rapport sur la Science et la Technologie n23, Académie des Sciences, Editions EDP Sciences, Paris.
  • Brochot C., Bois F., 2005, Use of a chemical probe to increase safety for human volunteers in toxicokinetic studies, Risk Analysis, 25:1559-1571.
  • Brochot C., Toth J., Bois F., 2005, Lumping in pharmacokinetics, Journal of Pharmacokinetics and Pharmacodynamics, 32:719-736.
  • Lemazurier E., Lecomte A., Robidel F., Bois F., 2005, Propylene glycol monomethyl ether - a 3-generation study of isomer Œ≤ effects on reproductive and developmental parameters in rats, Journal of Industrial Health, 21:33-40.
  • Micallef S., Brochot C., Bois F., 2005, [Bayesian statistical analysis of toxicokinetic data], Environnement, Risque et Sante, 4:21-34.
  • Diack C., Bois F., 2005, Pharmacokinetic-pharmacodynamic models for categorical toxicity data, Regulatory Toxicology and Pharmacology, 41:55-65.
  • Bois F., Diack C., 2005, Uncertainty Analysis: The Bayesian Approach in Quantitative Methods for Cancer and Human health Risk Assessment, Edler L., Kitsos C.P., Eds., Wiley, p. 255-266.
  • Motta A., Dormans J.A., Peltre G., Lacroix G., Bois F., Steerenberg P.A., 2004, Intratracheal instillation of Phleum pratense pollen cytoplasmicgranules induces a specific allergic reaction, International Archives of Allergy and Immunology, 135:24-29.
  • Motta A., Peltre G., Dormans J.A., Withagen C.E., Lacroix G., Bois F., Steerenberg P.A., 2004, Phleum pratense pollen starch granules induce humoral and cell-mediated immune responses in a rat model of allergy. Clinical and Experimental Allergy, 34:310-314.
  • Brochot C., Marchand S., Couet W., Gelman A., Bois F., 2004, Extension of the isobolographic approach to interactions studies between more than two drugs: Illustration with the convulsant interaction between pefloxacin, norfloxacin and theophylline in rats, Journal of Pharmaceutical Sciences, 93:553-562.
  • Micallef S., Bois F., 2004, [Application of physiological models to toxicokinetic data analysis], Journal de la Societe Francaise de Statistique, 145:15-32.
  • Bois F., Brochot C., 2004, Reducing the risk incurred by human volunteers in toxicokinetic studies through the use of tracers, Toxicology and Applied Pharmacology 197(3):365-365. (non refereed)
  • Brochot C., Bessoud B., Balvay D., Cuenod C.-A., Siauve N., Bois F., 2004, Bayesian physiologically based pharmacokinetic modeling of tumors' microcirculation magnetic resonance imaging data: Application to the evaluation of an antiangiogenic treatment, Toxicology and Applied Pharmacology 197(3):365-365. (non refereed)
  • Mezzetti M., Ibrahim J.G., Bois F., Ryan L.M., Ngo L., Smith T.J., 2003, A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism, Journal of the Royal Statistical Society, Series C, 52:291-305.
  • Lemazurier E., Multigner L., Lecomte A., Robidel F., Bois F., 2003, [Ethylene glycol methyl ether (EGME) and propylene glycol methyl ether (PGME) isomers: Mechanisms of their toxic effects on reproduction and development], Environnement, Risque et Sante, 2:89-96.
  • Bois F., 2003, [Toxicokinetic modelling of 2,3,7,8-tetrachloro-p-dioxin blood concentration after ingestion by women], Environnement, Risque et Sant√©, 2:45-53.
  • Kouniali A., Gonzalez-Flesca N., Dujardin R., Gehanno J.-F., Bois F., 2003, Environmental benzene exposure assessment for parent-child pairs in Rouen - France, Science of the Total Environment, 308:73-82.
  • Lacroix G., Tissot S., Rogerieux F., Beaulieu R., Cornu L., Gillet C., Robidel F., Lef√®vre J.-P., Bois F., 2002, Decrease in ovalbumin-induced pulmonary allergic response by benzaldehyde but not acetal¬≠de¬≠hyde exposure in a guinea pig model, Journal of Toxicology and Environmental Health, 65:995-1012.
  • Smith T., Lin Y.-S., Mezzetti L., Bois F., Kelsey K., Ibrahim J., 2001, Genetic and dietary factors affecting human metabolism of 1,3-butadiene, Chemico-Biological Interactions, 135-136 (special issue):407-428.
  • Jonsson F., Bois F., Johanson G., 2001, Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects, Archives of Toxicology, 75:189-199.
  • Bois F., 2001, Applications of population approaches in toxicology, Toxicology Letters, 120:385-394.
  • Jonsson F., Bois F., Johanson G., 2001, Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise, Toxicological Sciences, 59:209-218.
  • Bernillon P., Bois F., 2000, Statistical issues in toxicokinetic modeling: A Bayesian perspective, Environmental Health Perspectives, 108(suppl.5):883-893.
  • Cancré N., Tall A., Rogier C., Faye J., Sarr O., Trape J., Bois F., 2000, Bayesian analysis of an epidemiological model of P. falciparum malaria infection in Ndiop, Senegal, American Journal of Epidemiology, 152:760-770.
  • Bois F., 2000, Statistical Analysis of Fisher et al. PBPK model of trichloroethylene kinetics, Environmental Health Perspectives, 108(suppl. 2):275-282.
  • Bois F., 2000, Statistical Analysis of Clewell et al. PBPK model of trichloroethylene kinetics, Environmental Health Perspectives, 108(suppl. 2):307-316.
  • Bois F., 1999, Analysis of PBPK models for risk characterization, Annals of the New York Academy of Sciences, 895:317-337.
  • Johanson G., Jonsson F., Bois F., 1999, Development of new technique for risk assessment using physiologically based toxicokinetic models, American Journal of Industrial Medecine, 36(Suppl. 1):101-103.
  • Bois F., Smith T., Gelman A., Chang H.‚ÄëY., Smith A., 1999, Optimal design for a study of butadiene toxicokinetics in humans, Toxicological Sciences, 49:213-224.
  • Cancre N., Bois F., Gresenguet G., Fretz C., Fournel J.-J., B√©lec L., 1999, Screening blood donations for hepatitis C in central Africa: Analysis of a risk- and cost-based decision tree, Medical Decision Making, 19:296-306.
  • Bois F., 1999, The Bayesian approach to population pharmacokinetic/pharmacodynamic modeling - Discussion, in Case Studies in Bayesian Statistics, volume IV, Springer Verlag, New-York.
  • Hauck W., Tozer T., Anderson S., Bois F., 1998, Considerations in the attainment of steady state: Aggregate vs. individual assessment, Pharmaceutical Research, 15:1796-1798.
  • Bois F., Fahmy T., Block J.C., Gatel D., 1997, Dynamic modeling of bacteria in a pilot drinking water distribution system, Water Research, 31:3146-3156.
  • Gelman A., Bois F., 1997, Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials - Comment, Journal of the American Statistical Association, 92:1248-1250.
  • Bois F., Maszle D., 1997, MCSim: A simulation program, Journal of Statistical Software, 2(9):http://www.stat.ucla.edu/journals/jss/v02/i09.
  • Hauck W.H., Hauschke D., Diletti E., Bois F., Steinijans W., Anderson S., 1997, Choice of Student's t- or Wilcoxon-based confidence intervals for assessment of average bioequivalence, Journal of Biopharmaceutical Statistics, 7:179-189.
  • Hauck W.H., Preston P.E., Bois F., 1997, A group sequential approach to crossover trials for average bioequivalence, Journal of Biopharmaceutical Statistics, 7:87-96.
  • Hauck W., Bois F., Hyslop T., Gee L., Anderson S., 1997, A parametric approach to population bioequivalence, Statistics in Medicine, 16:441-454.
  • Bois F., 1997, Benzene toxicokinetics in humans, in Health and Toxicology, P.N. Cheremisinoff Ed., Advances in Environmental Control Technology Series, Gulf Publishing Company, Houston.
  • Gelman, A., Bois, F., 1997, How can statistical theory help with statistical practice? Example of a Bayesian analysis in toxicokinetics, in Good Statistical Practice ‚Äî Proceedings of the 12th International Workshop on Statistical Modelling (C.E. Minder and H. Friedl, Eds.). Austrian Statistical Society, Wien. (refereed)
  • Watanabe K., Bois F., 1996, Interspecies extrapolation of physiological pharmacokinetic parameter distributions, Risk Analysis, 16:741-754.
  • Gelman A., Bois F., Jiang J., 1996, Physiological pharmacokinetic analysis using population modeling and informative prior distributions, Journal of the American Statistical Association, 91:1400-1412.
  • Bois F., Jackson E., Pekari K., Smith M., 1996, Population toxicokinetics of benzene, Environmental Health Perspectives, 104(suppl. 6):1405-1411.
  • Tozer T.N., Bois F., Hauck W.H., Chen M.-L., Williams R., 1996, Absorption rate vs. exposure: Which is more useful for bioequivalence testing?, Pharmaceutical Research, 13:453-456.
  • Bois F., Gelman A., Jiang J., Maszle D., Zeise L., Alexeef G., 1996, Population toxicokinetics of tetrachloroethylene, Archives of Toxicology, 70:347-355.
  • Hauck W., Hyslop T., Anderson S., Bois F., Tozer T., 1995, Statistical and regulatory considerations for multiple measures in bioequivalence testing, Clinical Research and Regulatory Affairs, 12:249-265.
  • Bois F., Krowech G., Zeise L., 1995, Modeling human interindividual variability in metabolism and risk: The example of 4-aminobiphenyl, Risk Analysis, 15:205-213.
  • Thouand G., Friant P., Bois F., Cartier A., Maul A., Block J.C., 1995, Bacterial inoculum density and probability of para-nitrophenol biodegradability test response, Ecotoxicology and Environmental Safety, 30:274-282.
  • Tozer T., Bois F., 1995, Metrics of absorption: Simulation approach, in Bio-International 2 - Bioavailability, Bioequivalence and Pharmacokinetic Studies (H.H. Blume and K.K. Midha, Eds.), pp. 51–60. Medpharm Scientific Publishers, Stuttgart. (non refereed)
  • Eisenberg J.N., Seto E., Bois F., Spear R.C., 1995, A population model describing the epidemiology of water-borne disease: A case study on the risk of Giardiasis via reclaimed water in a recreational swimming impoundment, in Assessing and Managing Health Risks from Drinking Water Contamination: Approaches and Applications, E.G. Reichard and G.A. Zapponi Eds, International Association of Hydrological Sciences Publication No. 233, Oxfordshire, UK.
  • Spear R., Bois F., 1994, Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results, Environmental Health Perspectives, 102(suppl. 11):61-66.
  • Woodruff T.J., Kyle A., Bois F., 1994, Evaluating health risks from occupational exposures to pesticides and the regulatory response, Environmental Health Perspectives, 102:1088-1096.
  • Bois F., Tozer T.N., Hauck W.H., Chen M.-L., Patnaik R., Williams R., 1994, Bioequivalence: Performance of several measures of rate, Pharmaceutical Research, 11:966-974.
  • Bois F., Eskenazi B., 1994, Possible risk of endometriosis for Seveso (Italy) residents - An assessment of exposure levels, Environmental Health Perspectives, 102:476-477.
  • Watanabe K.H., Bois F., Daisey J.M., Auslander D.M., Spear R.C., 1994, Benzene toxicokinetics in humans ‚Äì Bone marrow exposure to metabolites, Occupational and Environmental Medicine, 51:414-420.
  • Bois F., Tozer T.N., Hauck W.H., Chen M.-L., Patnaik R., Williams R., 1994, Bioequivalence: Performance of several measures of extent, Pharmaceutical Research, 11:715-722.
  • Eisenberg J., Seto E., Bois F., Spear R., 1994, A population model describing the epidemiology of water-borne disease: A case study on the risk of Giardiasis via reclaimed water in a recreational swimming impoundment, in Proceedings of the International Symposium on Assessing and Managing Health Risks from Drinking Water Contamination: Approaches and Applications. International Association of Hydrological Sciences, Roma, Italia. (refereed)
  • Woodruff T.J., Bois F., 1993, Optimization issues in physiological toxicokinetic modeling: A case study with benzene, Toxicology Letters, 69:181-196.
  • Reigner B.G., Bois F., Tozer T.N., 1993, Pentachlorophenol carcinogenicity: Extrapolation of risks from mice to humans, Human and Experimental Toxicology, 12:215-225.
  • Maszle D., Bois F., 1993, Program MCSim - User Manual, Simulation program developed and distributed for Unix, Microsoft DOS, and Macintosh platforms.
  • Reigner B.G., Gungon R.A., Bois F., Zeise L., Tozer T.N., 1992, Pharmacokinetic concepts in assessing intake of pentachlorophenol after exposure in drinking water, Pharmaceutical Research, 81:1113-1118.
  • Bois F., Compton-Quintana P., 1992, Sensitivity analysis of a new model of carcinogenesis, Journal of Theoretical Biology, 159:361-375.
  • Bois F., Paxman D., 1992, An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model, Regulatory Toxicology and Pharmacology, 15:122-136.
  • Reigner B.G., Bois F., Tozer T.N., 1992, Assessment of pentachlorophenol exposure in humans using the clearance concept, Human and Experimental Toxicology, 11:17-26.
  • Watanabe K., Bois F., Zeise L., 1992, Interspecies extrapolation: A reexamination of acute toxicity data, Risk Analysis, 12:301-310.
  • Woodruff T., Bois F., Auslander D., Spear R., 1992, Structure and parametrization of toxicokinetic models: Their impact on model predictions, Risk Analysis, 12:189-201.
  • Bois F., Woodruff T., Spear R., 1991, Comparison of three physiologically-based pharmacokinetic models of benzene disposition, Toxicology and Applied Pharmacology, 110:79-88.
  • Spear R., Bois F., Woodruff T., Auslander D., Parker J., Selvin S., 1991, Modeling benzene pharmacokinetics: Calibration and parametric sensitivity across three sets of animal data, Risk Analysis, 11:641-654.
  • Bois F., Smith M., Spear R., 1991, Mechanisms of benzene carcinogenesis: Application of a physiological model of benzene pharmacokinetics and metabolism, Toxicology Letters, 56:283-298.
  • Spear R., Bois F., 1991, Exposure assessment and cancer risk models: An engineering perspective, in Proceedings of the 1990 Pacific Basin Conference on Hazardous Waste (R.R. Cirillo and R.A. Carpenter, Eds.), pp. 412–418. Pacific Basin Consortium for Hazardous Waste Research, Honolulu. (non refereed)
  • Bois F., Zeise L., Tozer T.N., 1990, Precision and sensitivity analysis of pharmacokinetic models for cancer risk assessment: Tetrachloroethylene in mice, rats and humans, Toxicology and Applied Pharmacology, 102:300-315.
  • Woodruff T., Bois F., Parker J., Auslander D., Selvin S., Spear R., 1990, Parameterization of a physiologically-based pharmacokinetic (PBPK) model using three different experiments, in Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 12. IEEE. (refereed)
  • Bois F., Tozer T.N., Benet L.Z., Zeise L., 1989, Lead exposure in children vs. adults (Letter), American Journal of Public Health, 79:904.
  • Bois F., Tozer T.N., Zeise L., Benet L.Z., 1989, Application of clearance concepts to the assessment of exposure to lead in drinking water, American Journal of Public Health, 79:827-831.
  • Woodruff T., Bois F., Parker J., Auslander D., Selvin S., Smith M., Spear R., 1989, Design and analysis of a model of benzene toxicokinetics in mammals, in Images of the Twenty-First Century - Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 11 (Y. Kim and F.A. Spelman, Eds.), pp. 254–255. IEEE #89CH2770-6. (refereed)
  • Bois F., Tozer T.N., Zeise L., 1989, The use of pharmacokinetic models in the determination of risks for regulatory purposes, In Advances in Risk Analysis vol.7 - Proceedings of the 1987 Annual Meeting of the Society for Risk Analysis (J.J. Bonin and D.E. Stevenson, Eds.), pp. 573–583. Plenum Publishing Corporation, New-York. (refereed)
  • Bois F., Gravil P.J., Vasseur P., Isoard P., 1988, Optimal pollution control strategies in the presence of interacting toxicants, Water Research, 22:1443-1447.
  • Bois F., 1988, Modelisation Mathematique de la Cancérogenèse par des Produits Chimiques, 130 p. with appendices, Ph.D. thesis. Universite de Metz, Mention Sciences, Metz.
  • Bois F., Vasseur P., 1987, Carcinogenesis modeling for cancer risk estimation: Conditions of application to drinking water, Science des Aliments, 7:301-306.
  • Bois F., Vaillant M., Vasseur P., 1986, Multiple regression analysis of toxic interactions: Application to the Microtox test and general comments, Bulletin of Environmental Contamination and Toxicology, 36:707-714.
  • Bois F., Vasseur P., 1985, Synergism in carcinogenesis (Letter to the Editor) Journal of the National Cancer Institute, 74:729.
  • Vasseur P., Bois F., Ferard J.F., Rast C., Larbaigt G., 1985, Influence of physico-chemical parameters on the Microtox test response, Toxicity Assessment: An International Quarterly, 1:283-300.
  • Bois F., 1984, Influence de Paramètres Physico-Chimiques du Milieu sur la Toxicite des Produits Chimiques: Cas du Zinc et du Pentachlorophenol, 76 p. Rapport de Diplôme d'Etudes Approfondies en Toxicologie (Research Thesis), Metz.
  • Vasseur P., Bois F., Ferard J.F., 1984, [Genotoxicity of drinking water extracts and concentrates], in Livre Jubilaire de la Chaire de Toxicologie de Paris, Hommage a Rene Truhaut, Faculte de Pharmacie de Paris, 1248¬†p.
  • Bois F., 1981, Pharmacologie de la Monoamine Oxydase, Eude de l'Effet du Lithium sur l'Enzyme chez la Souris, 81 p., Pharmacy Doctorate Thesis, Nancy.

References

  1. ↑ 1.0 1.1 Anonymous. "Le comité de la prévention et de la précaution, F. Bois biography" (in French). http://www.developpement-durable.gouv.fr/Le-comite-de-la-prevention-et-de,15001.html. Retrieved 11 January 2013. 
  2. ↑ Society of Environmental Toxicology and Chemistry (SETAC). "About the speakers". 1st SETAC Europe Special Science Symposium. SETAC. http://reach.setac.eu/programme/about_the_speakers/?contentid=73. Retrieved 11 January 2013. 
  3. ↑ Anonymous. "Certara Adds 4 Global Leaders to its Simcyp PBPK, QSP and QSTS M&S Division". https://www.certara.com/pressreleases/certara-adds-four-global-leaders-to-its-simcyp-pbpk-qsp-and-qsts-modeling-and-simulation-division/?ap%5B0%5D=CSC&ap%5B1%5D=PBPK. Retrieved 15 May 2019. 
  4. ↑ Anonymous. "In Silico Pharmacology Editorial Board". Springer Verlag. http://www.in-silico-pharmacology.com/about/edboard. Retrieved 11 January 2013. 
  5. ↑ Anonymous. "Environnement Risque et Santé Editorial Board". Joh Libbey Eurotext. http://www.jle.com/en/revues/sante_pub/ers/e-docs/00/00/00/15/comite.md?type=text.html. Retrieved 11 January 2013. 
  6. ↑ Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. US National Academy of Sciences. pp. 216. ISBN 978-0-309-10988-8. http://www.nap.edu/openbook.php?record_id=11970&page=1. 
  7. ↑ Board on Environmental Studies and Toxicology. "Committee members of the Standing Committee on Risk Analysis Issues and Reviews". The National Academies. http://dels-old.nas.edu/best/risk_analysis/committee.shtml. Retrieved 11 January 2013. 
  8. ↑ "Outstanding Statistical Application Award". American Statistical Association. http://www.amstat.org/awards/outstandingstatisticalapplicationaward.cfm. Retrieved 11 January 2013. 

External links





Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:Frédéric_Y._Bois&oldid=419550"